Specifically, SDA achieved 91% accuracy for ILC vs IDC cross-validated tumor classification, 91% for ER+ vs ER- cell line prediction and 86% for BRCA vs other cancers in cell line prediction. The gene discussed is ESR1; the disease is neoplasm.